Our Partners
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
Search
Search results
Therapy development updates
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
ProQR makes progress with potential treatment for LCA
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
Download our Knowledge-base material
Download copies of our Knowledge-base material
Types of inherited sight loss
Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Tyne & Wear Local Peer Support Group
Saturday 28 March 2026, 1.00pm - 7.00pm - In-person - Come and join Colin and the group at the Tyneside Irish Centre for their first in-person event of 2026.